Your browser is no longer supported. Please, upgrade your browser.
Settings
PTLA Portola Pharmaceuticals, Inc. daily Stock Chart
PTLA [NASD]
Portola Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.55 Insider Own0.10% Shs Outstand66.51M Perf Week-7.46%
Market Cap3.38B Forward P/E- EPS next Y-1.82 Insider Trans-97.03% Shs Float63.60M Perf Month-7.42%
Income-258.10M PEG- EPS next Q-1.46 Inst Own82.90% Short Float5.77% Perf Quarter-21.65%
Sales31.90M P/S106.06 EPS this Y-9.30% Inst Trans0.83% Short Ratio3.85 Perf Half Y34.26%
Book/sh1.95 P/B26.09 EPS next Y62.40% ROA-79.00% Target Price66.37 Perf Year145.87%
Cash/sh4.06 P/C12.54 EPS next 5Y- ROE-147.60% 52W Range15.68 - 67.10 Perf YTD126.69%
Dividend- P/FCF- EPS past 5Y- ROI-112.00% 52W High-24.19% Beta1.27
Dividend %- Quick Ratio4.90 Sales past 5Y-14.60% Gross Margin- 52W Low224.43% ATR1.98
Employees163 Current Ratio4.90 Sales Q/Q-9.50% Oper. Margin- RSI (14)38.28 Volatility3.28% 3.71%
OptionableYes Debt/Eq0.92 EPS Q/Q-20.10% Profit Margin- Rel Volume0.63 Prev Close50.87
ShortableYes LT Debt/Eq0.92 EarningsNov 08 AMC Payout- Avg Volume951.17K Price50.87
Recom1.60 SMA20-4.98% SMA50-8.94% SMA20015.48% Volume0 Change0.00%
Aug-24-17Upgrade Credit Suisse Neutral → Outperform
Jun-26-17Reiterated Morgan Stanley Overweight $50 → $70
Jun-26-17Reiterated Citigroup Buy $51 → $78
Feb-24-17Upgrade Oppenheimer Perform → Outperform
Jan-03-17Upgrade Citigroup Neutral → Buy
Dec-27-16Reiterated Credit Suisse Outperform $20 → $29
Aug-19-16Downgrade Citigroup Buy → Neutral
May-31-16Downgrade Credit Suisse Outperform → Neutral $33 → $30
Mar-28-16Reiterated Credit Suisse Outperform $47 → $34
Mar-28-16Downgrade Goldman Buy → Neutral $65 → $30
Dec-18-15Initiated Goldman Buy
Oct-11-17 04:05PM  Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots GlobeNewswire
Oct-09-17 08:05AM  See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc. Markit
Oct-03-17 04:05PM  Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-02-17 08:02AM  See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc. Markit
Sep-26-17 06:58PM  Cramer's lightning round: Portola's no one-trick pony CNBC Videos
08:05AM  See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc. Markit
Sep-20-17 08:00AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Synchronoss Technologies ACCESSWIRE
Sep-19-17 09:39AM  Is It The Right Time To Buy Portola Pharmaceuticals Inc (PTLA)? Simply Wall St. -7.92%
Sep-13-17 09:06AM  Portola Shares Lower After Pricing Stock Offering - Biotech Movers TheStreet.com
Sep-12-17 10:39PM  Portola Announces Pricing of Public Offering of Common Stock GlobeNewswire
08:04AM  See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc. Markit
Sep-11-17 04:01PM  Portola Pharmaceuticals Announces Proposed Offering of Common Stock GlobeNewswire
Sep-07-17 02:10PM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Portola Pharmaceuticals, Inc. Investors (PTLA) Business Wire
Sep-06-17 05:46PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Portola Pharmaceuticals, Inc. Business Wire
04:01PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Portola Pharmaceuticals Inc. (PTLA) PR Newswire
02:04PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Portola Pharmaceuticals Inc. - PTLA PR Newswire
08:00AM  Today's Research Reports on Trending Tickers: Pulmatrix Inc. and Portola Pharmaceuticals Inc. ACCESSWIRE
08:00AM  Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare Conference GlobeNewswire
Sep-05-17 08:00AM  Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch GlobeNewswire -5.47%
Sep-01-17 06:34PM  Portola Pharmaceuticals to Host Webcast and Conference Call Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch GlobeNewswire
Aug-25-17 05:17PM  ETFs with exposure to Portola Pharmaceuticals, Inc. : August 25, 2017 Capital Cube
11:03AM  [$$] Down With Teva, Up With Portola Barrons.com
08:41AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : August 25, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. ACCESSWIRE
Aug-23-17 08:04AM  See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc. Markit
Aug-21-17 08:00AM  Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the European Society of Cardiology (ESC) Congress 2017 GlobeNewswire
Aug-17-17 10:22AM  FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa Zacks
07:40AM  Featured Company News - Portola Pharmaceuticals' AndexXa(R) Biologics License Application Resubmission Accepted for Review by US FDA ACCESSWIRE
Aug-16-17 10:49AM  Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Capital Cube
Aug-15-17 08:00AM  Portola Pharmaceuticals Announces AndexXa® (Andexanet Alfa) Biologics License Application Resubmission Accepted for Review by U.S. FDA GlobeNewswire
Aug-13-17 10:05AM  Edited Transcript of PTLA earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-12-17 08:05AM  See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc. Markit
Aug-11-17 08:10AM  Today's Research Reports on Stocks to Watch: Portola Pharmaceuticals and BioDelivery Sciences International ACCESSWIRE
Aug-10-17 10:01AM  These Biotech Stocks are BOOMING TheStreet.com -7.19%
08:05AM  IHS Markit Score downgrades Portola Pharmaceuticals Inc to 30 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
12:33AM  Portola Pharmaceuticals posts 2Q loss Associated Press
Aug-09-17 04:25PM  Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
01:00PM  Investor Network: Portola Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 04:13PM  Portola Pharmaceuticals Announces Resubmission of Biologics License Application for AndexXa® (Andexanet Alfa) GlobeNewswire
Aug-02-17 08:00AM  Portola Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9 GlobeNewswire
Jul-27-17 04:09PM  Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-20-17 07:01PM  Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All TheStreet.com
Jul-19-17 07:00PM  Cramer Remix: Snap is the No. 1 reason to own Facebook CNBC
Jul-14-17 07:19AM  Is It Time to Sell Portola? Motley Fool
Jul-13-17 07:30AM  Portola's Hitting All-Time Highs: Here's Why the Stock Should Go Higher Motley Fool
Jul-11-17 07:18AM  How Portola Is Looking to Change the Anticoagulant Game Motley Fool
Jul-06-17 02:35PM  What Was Behind Portola Pharmaceuticals' 45% Pop? Motley Fool
08:00AM  Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Scientific and Standardization Committee Meeting GlobeNewswire
Jul-05-17 09:01PM  Why Portola Pharmaceuticals Skyrocketed 54% in June Motley Fool
11:44AM  3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates Motley Fool
Jul-02-17 07:21AM  The CBO Trips Up Trumpcare, Plus a Biotech "Spiffy-Pop Motley Fool
Jun-29-17 04:43PM  Is It Too Late to Buy Portola Pharmaceuticals Stock? Motley Fool
Jun-28-17 03:30PM  These 3 Small Biotechs Have a Healthy Shot TheStreet.com
Jun-27-17 04:27PM  These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing? Motley Fool
08:15AM  Corporate News Blog - US FDA Approves Portola's Anticoagulant for High-risk Patients with Thromboembolic Complications Accesswire
Jun-26-17 12:54PM  Oppenheimer Boosts Price Target for Portola Pharmaceuticals Inc (PTLA) Following FDA Approval SmarterAnalyst
10:16AM  Company News for June 26, 2017 Zacks
10:05AM  Edited Transcript of PTLA earnings conference call or presentation 8-May-17 8:30pm GMT Thomson Reuters StreetEvents
08:30AM  Biotech Stocks Showing Signs of Resurgence PR Newswire
08:00AM  Today's Research Reports on Stocks to Watch: Portola and AVEO Accesswire
Jun-24-17 08:03AM  Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest Motley Fool
Jun-23-17 04:29PM  Why Synchronoss Technologies, AK Steel Holding, and Portola Pharmaceuticals Jumped Today Motley Fool +46.56%
03:58PM  Portola Pharmaceuticals Inc.'s Green Light Sends Its Stock Soaring as Much as 51% Motley Fool
03:18PM  Portola shares soar after FDA approves clot preventing drug Reuters
02:00PM  Portola Pharma stock skyrockets after FDA approves anticoagulant for high-risk patients MarketWatch
01:44PM  FDA approves Portola's blood-thinning drug CNBC Videos
01:04PM  U.S. FDA Approves Bevyxxa® (betrixaban) First and Only Anticoagulant for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients GlobeNewswire
12:16PM  U.S. FDA approves Portola blood-thinner to prevent blood clots Reuters
10:52AM  Citi Says Expect FDA PDUFA Decision For Portola Pharma Early Benzinga
Jun-21-17 08:07AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : June 21, 2017 Capital Cube
08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Lipocine and Portola Pharmaceuticals Accesswire
Jun-20-17 08:43AM  Implied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock Options Zacks +6.85%
06:30AM  Here Comes a Big Breakout For Alibaba TheStreet.com
Jun-15-17 08:30AM  Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma GlobeNewswire
Jun-09-17 01:53PM  ETFs with exposure to Portola Pharmaceuticals, Inc. : June 9, 2017 Capital Cube
Jun-05-17 07:47AM  Key FDA Events to Watch Out for in Jun 2017 Zacks
Jun-02-17 01:27PM  Portola Pharmaceuticals Could Be a Great June Trade GuruFocus.com
May-28-17 03:20PM  Two Red Hot Biotechs With Big Near-term Catalysts Ahead Motley Fool
May-22-17 02:02PM  ETFs with exposure to Portola Pharmaceuticals, Inc. : May 22, 2017 Capital Cube
08:38AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : May 22, 2017 Capital Cube
08:07AM  These 3 Biotech Stocks Have Ballooned in 2017, but Will They Pop? Motley Fool
May-18-17 08:00AM  Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA) GlobeNewswire
May-11-17 05:23PM  ETFs with exposure to Portola Pharmaceuticals, Inc. : May 11, 2017 Capital Cube
09:17AM  3 Top Biotech Stocks For May Motley Fool
May-10-17 10:14AM  Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-09-17 05:50PM  Why Portola Pharmaceuticals Shot 12.8% Higher Today Motley Fool +12.78%
05:39PM  Portola Pharmaceuticals, Inc. Value Analysis (NASDAQ:PTLA) : May 9, 2017 Capital Cube
09:00AM  Edited Transcript of PTLA earnings conference call or presentation 8-May-17 8:30pm GMT Thomson Reuters StreetEvents
08:00AM  Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML) GlobeNewswire
May-08-17 06:20PM  Portola Pharmaceuticals posts 1Q loss Associated Press
04:36PM  Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
11:00AM  Investor Network: Portola Pharmaceuticals, Inc. to Host Earnings Call Accesswire
09:11AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : May 8, 2017 Capital Cube
May-01-17 08:00AM  Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8 GlobeNewswire
Apr-17-17 09:01AM  Why Shares of Portola Pharmaceuticals Are Up Over 60% in 2017 Motley Fool
Apr-10-17 10:04AM  Losing Money on a Stock? Blame Your Brain Motley Fool
Apr-05-17 05:19PM  ETFs with exposure to Portola Pharmaceuticals, Inc. : April 5, 2017 Capital Cube
Apr-04-17 08:48AM  3 Hot Stocks to Buy in April Motley Fool
Mar-31-17 12:00PM  My 3 Top Biotech Stocks to Buy Now Motley Fool
Mar-16-17 09:22AM  Why Portola Pharmaceuticals Stock Is Already Up an Eye-Popping 72% This Year Motley Fool
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wolff Henry WardDirectorOct 05Option Exercise5.3012,00063,60012,000Oct 06 08:30 PM
Curnutte John TExecutive Vice PresidentSep 28Option Exercise7.4821,000157,07314,285Sep 29 06:24 PM
Curnutte John TExecutive Vice PresidentJul 18Option Exercise8.5010,00085,00010,000Jul 20 06:53 PM
Fu TaoEVP, CBOJul 18Option Exercise33.495,812194,6445,812Jul 20 07:00 PM
Curnutte John TExecutive Vice PresidentJul 18Sale65.0010,000650,0000Jul 20 06:53 PM
Fu TaoEVP, CBOJul 18Sale65.005,812377,7800Jul 20 07:00 PM
Dier MardiExecutive VP and CFOJul 11Option Exercise25.0823,350585,61823,350Jul 13 05:54 PM
Dier MardiExecutive VP and CFOJul 11Sale60.0023,3501,401,0000Jul 13 05:54 PM
Lis WilliamChief Executive OfficerJun 28Option Exercise9.0014,150127,35014,150Jun 29 08:15 PM
Lis WilliamChief Executive OfficerJun 28Sale55.3514,150783,2030Jun 29 08:15 PM
Dier MardiExecutive VP and CFOJun 27Option Exercise18.5993,3921,736,00960,937Jun 28 06:05 PM
Lis WilliamChief Executive OfficerJun 27Option Exercise8.29255,1492,116,24395,850Jun 29 08:15 PM
Lis WilliamChief Executive OfficerJun 27Sale55.44255,14914,144,9210Jun 29 08:15 PM
Dier MardiExecutive VP and CFOJun 27Sale55.4693,3925,179,8250Jun 28 06:05 PM
Fu TaoEVP, CBOJun 26Option Exercise33.493,000100,4703,000Jun 27 04:56 PM
Curnutte John TExecutive Vice PresidentJun 26Option Exercise8.5060,000510,00060,000Jun 28 05:58 PM
Curnutte John TExecutive Vice PresidentJun 26Sale57.8860,0003,472,9550Jun 28 05:58 PM
Fu TaoEVP, CBOJun 26Sale60.003,000180,0000Jun 27 04:56 PM
HOMCY CHARLES JDirectorJun 23Option Exercise5.00120,803604,015120,803Jun 27 04:51 PM
Fu TaoEVP, CBOJun 23Option Exercise28.314,000113,2582,604Jun 27 04:56 PM
Fu TaoEVP, CBOJun 23Sale55.004,000220,0000Jun 27 04:56 PM
HOMCY CHARLES JDirectorJun 23Sale53.06120,8036,409,8070Jun 27 04:51 PM
BIRD JEFFREY WDirectorJun 01Buy31.85119,4423,804,025921,610Jun 02 06:17 PM
Maxwell (Mauritius) Pte Ltd10% OwnerJun 01Sale34.401,700,00058,480,0004,133,568Jun 05 08:01 AM
Lis WilliamChief Executive OfficerApr 11Sale36.066,750243,4054,730Apr 11 04:34 PM
Fu TaoEVP, CBOApr 10Sale36.971,09740,5560Apr 11 04:31 PM
Dier MardiExecutive VP and CFOMar 15Option Exercise7.6310,23578,0955,935Mar 16 06:45 PM
HOMCY CHARLES JDirectorMar 15Option Exercise5.0050,000250,00050,000Mar 16 06:18 PM
Dier MardiExecutive VP and CFOMar 15Sale40.0210,235409,6050Mar 16 06:45 PM
HOMCY CHARLES JDirectorMar 15Sale40.0650,0002,003,0000Mar 16 06:18 PM
HOMCY CHARLES JDirectorMar 01Option Exercise5.0025,000125,00025,000Mar 03 05:02 PM
HOMCY CHARLES JDirectorMar 01Sale37.5025,000937,5000Mar 03 05:02 PM